RJ 4960
Alternative Names: RJ-4960Latest Information Update: 20 Sep 2023
At a glance
- Originator Nanjing Ruijie Pharma
- Class
- Mechanism of Action Syk kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified